Clinical Trial

A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This pan-tumor trial is designed as a signal-seeking trial to assess efficacy and safety of raludotatug deruxtecan (R-DXd) monotherapy in locally advanced or metastatic solid tumors with various cadherin-6 (CDH6) expression levels, including gynecological cancers (endometrial cancer, cervical cancer, and non-high-grade serous ovarian cancer) and genitourinary cancers (urothelial cancer and clear cell renal cell carcinoma \[ccRCC\]).
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2024-10-25; most recent amendment 2026-05-27.
Status change: Recruiting → Active, Not Recruiting 2026-05-27
Status change: Not Yet Recruiting → Recruiting 2025-03-06
Trial Details
NCT Number NCT06660654
Lead Sponsor Daiichi Sankyo
Collaborators: Merck Sharp & Dohme LLC
Conditions Advanced Solid Tumor, Metastatic Solid Tumors
Enrollment 200 participants
Start Date 2025-01-06
Primary Completion 2027-09-30 (estimated)
Study Completion 2027-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-29